Copyright
©The Author(s) 2016.
World J Gastroenterol. Mar 14, 2016; 22(10): 2993-3005
Published online Mar 14, 2016. doi: 10.3748/wjg.v22.i10.2993
Published online Mar 14, 2016. doi: 10.3748/wjg.v22.i10.2993
Table 1 Baseline characteristics of 316 patients with 404 hepatocellular carcinomas n (%)
| Characteristics | Value |
| Age (yr) | |
| Mean (range) | 60.1 ± 10.8 (24-87) |
| Patients aged ≥ 60 yr | 140 (44.3) |
| Sex | |
| Males | 250 (79.1) |
| Females | 66 (20.9) |
| Etiology of cirrhosis | |
| HBV | 231 (86.6) |
| HCV | 37 (10.2) |
| Alcohol | 4 (1.9) |
| Others | 6 (1.3) |
| Pre-RFA serum AFP | |
| < 20 ng/mL | 177 (56.0) |
| ≥ 20 ng/mL | 139 (44.0) |
| Child-Pugh class | |
| A | 250 (77.0) |
| B | 57 (20.1) |
| C | 9 (2.8) |
| Serum ALT/AST | |
| Normal | 229 (72.5) |
| Elevated | 87 (27.5) |
| Tumor no | |
| Single | 248 (78.4) |
| ≥ 2 | 68 (21.6) |
| Tumor size (cm) | |
| Mean (range) | 3.2 ± 1.1(1.0-5.0) |
| Tumor > 3 cm | 169 (53.4) |
Table 2 Potential prognostic variables and their class scores in hepatocellular carcinomas patients
| Variables | Definition | Class scores1 |
| X1 | Sex | Male (1), Female (2) |
| X2 | Age (yr) | 18-60 (1), ≥ 60 (2) |
| X3 | Pathological grade | Well-Moderate differentiated (1), Poor-differentiated (2) |
| X4 | Etiology of cirrhosis | HBV (1), HCV (2), Alcohol (3), Others (4) |
| X5 | Portal vein hypertension | No (1), Yes (2) |
| X6 | Liver function enzyme | Normal (1), Elevated (2) |
| (serum AST/ALT) | ||
| X7 | Child-Pugh classification | A (1), B (2), C (3) |
| X8 | Serum AFP (ng/mL) | Normal < 20 (1), Abnormal ≥ 20 (2) |
| X9 | CEUS pre-RFA | No (1), Yes (2) |
| X10 | Number of tumors | Single (1), ≥ 2 (2) |
| X11 | Tumor size (cm) | ≤ 3.0 (1), 3.0-5.0 (2) |
| X12 | Risky location | No (1), Yes (2) |
| X13 | Type of RFA electrodes | Umbrella (1), single (2) |
| X14 | Primary technical success | Yes (0), No (1) |
| X15 | Number of RFA sessions | 1 (0), ≥ 2 (1) |
Table 3 Number of patients followed up for 1-10 years
| Follow-up (yr) | No. of patients | Cumulative frequency1 |
| 1 | 82 | 316 (100) |
| 3 | 53 | 234 (74.1) |
| 5 | 45 | 181 (57.3) |
| 7 | 65 | 136 (43.0) |
| 10 | 71 | 71 (22.5) |
Table 4 Kaplan meier univariate analysis of overall accumulative survival in 316 hepatocellular carcinoma patients after radiofrequency ablation
| Variable | No. of patients | Survival rate (%) | P value | ||||
| 1-yr | 3-yr | 5-yr | 7-yr | 10-yr | |||
| Sex | 0.570 | ||||||
| Male | 250 | 89.8 | 70.4 | 53.2 | 44.8 | 33.0 | |
| Female | 66 | 90.7 | 72.1 | 37.8 | 23.6 | - | |
| Age (yr) | 0.163 | ||||||
| < 60 | 176 | 90.3 | 67.6 | 48.0 | 31.7 | 26.4 | |
| ≥ 60 | 140 | 89.6 | 75.8 | 58.0 | 55.4 | 25.2 | |
| Pathology grade | < 0.001 | ||||||
| Well-Moderate differentiated | 126 | 94.4 | 82.5 | 64.2 | 53.0 | 42.5 | |
| Poor-differentiated | 78 | 83.6 | 51.9 | 33.1 | 26.5 | 16.1 | |
| Etiology of cirrhosis | 0.474 | ||||||
| HBV | 231 | 91.2 | 72.8 | 55.1 | 36.1 | 21.7 | |
| HCV | 37 | 95.8 | 76.7 | 57.5 | 57.5 | - | |
| Portal vein hypertension | < 0.001 | ||||||
| No | 211 | 94.2 | 78.5 | 63.0 | 51.8 | 36.2 | |
| Yes | 103 | 79.8 | 53.2 | 30.2 | 20.4 | 10.2 | |
| Liver function enzyme | 0.489 | ||||||
| Normal | 229 | 89.0 | 73.5 | 54.4 | 42.1 | 30.0 | |
| Elevated | 87 | 92.2 | 64.1 | 45.6 | 40.5 | - | |
| Child-Pugh classification | < 0.001 | ||||||
| A | 250 | 94.1 | 78.9 | 60.1 | 50.5 | 33.6 | |
| B | 57 | 82.5 | 46.8 | 25.9 | 17.2 | 17.2 | |
| C | 9 | 28.6 | 14.3 | 0 | 0 | 0 | |
| Serum AFP (ng/mL) | 0.037 | ||||||
| Normal | 177 | 88.4 | 75.1 | 59.2 | 53.3 | 35.4 | |
| Abnormal | 139 | 91.8 | 66 | 42.1 | 25.7 | 22.1 | |
| CEUS pre-RFA | < 0.001 | ||||||
| No | 83 | 80.1 | 56.2 | 37.7 | 26.1 | 18.0 | |
| Yes | 233 | 93.8 | 77.1 | 59.7 | 54.4 | - | |
| Number of tumors | < 0.001 | ||||||
| Single | 248 | 90.6 | 75.3 | 59.3 | 46.8 | 34.5 | |
| ≥ 2 | 68 | 87.6 | 54.6 | 27.0 | 21.6 | 10.8 | |
| Tumor size (cm) | 0.178 | ||||||
| ≤ 3.0 | 147 | 94.0 | 71.6 | 59.2 | 49.0 | 18.4 | |
| 3.0-5.0 | 169 | 86.8 | 69.8 | 47.3 | 36.4 | 25.2 | |
| Risky location | 0.668 | ||||||
| No | 152 | 91.4 | 71.5 | 48.6 | 41.6 | 32.7 | |
| Yes | 164 | 88.6 | 70.0 | 53.1 | 40.6 | 27.7 | |
| Type of RFA electrodes | <0.001 | ||||||
| Umbrella | 213 | 86.8 | 64.3 | 45.7 | 36.7 | 23.6 | |
| Single | 103 | 97.5 | 94.1 | 62.7 | 62.7 | - | |
| Primary technical success | 0.006 | ||||||
| Yes | 301 | 89.9 | 69.1 | 51.4 | 39.6 | 30.6 | |
| No | 15 | 54.5 | 36.4 | 18.2 | 0 | 0 | |
| Number of RFA sessions | 0.793 | ||||||
| 1 | 256 | 90.2 | 70.1 | 53.4 | 40.3 | 31.0 | |
| ≥ 2 | 60 | 89.3 | 73.4 | 49.0 | 42.4 | 30.3 | |
Table 5 Cox survival analysis of predictors of overall accumulative survival in 316 hepatocelluar carcinom patients after radiofrequency ablation
| Characteristic | Univariate | Multivariate | ||||
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Sex | 1.149 | 0.709-1.862 | 0.572 | |||
| Age | 0.754 | 0.506-1.125 | 0.166 | |||
| Pathology grade | 2.509 | 1.593-3.952 | < 0.001 | |||
| Etiology of cirrhosis | 0.862 | 0.720-1.031 | 0.105 | |||
| Portal vein hypertension | 2.686 | 1.826-3.951 | < 0.001 | 2.743 | 1.462-5.149 | 0.002 |
| Liver function enzyme (AST/ALT) | 1.162 | 0.758-1.780 | 0.491 | |||
| Child-Pugh classification | 3.210 | 2.297-4.488 | < 0.001 | 4.054 | 2.346-7.005 | < 0.001 |
| Serum AFP | 1.501 | 1.021-2.206 | 0.039 | |||
| CEUS pre-RFA | 0.438 | 0.295-0.651 | < 0.001 | |||
| Number of tumor | 2.293 | 1.518-3.463 | < 0.001 | 2.693 | 1.399-5.185 | 0.003 |
| Tumor size | 1.318 | 0.879-1.978 | 0.181 | |||
| Risky location | 1.090 | 0.735-1.616 | 0.670 | |||
| Type of RFA electrodes | 0.191 | 0.077-0.473 | < 0.001 | |||
| Primary technical success | 2.592 | 1.269-5.296 | 0.009 | |||
| Number of RFA sessions | 0.955 | 0.703-1.298 | 0.769 | |||
Table 6 Cox survival analysis of predictors of local progression-free survival in 316 patients with 404 hepatocelluar carcinomas after radiofrequency ablation
| Characteristic | Univariate | Multivariate | ||||
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Sex | 1.073 | 0.691-1.667 | 0.753 | |||
| Age | 0.796 | 0.559-1.133 | 0.205 | |||
| Pathological grade | 2.258 | 1.506-3.385 | < 0.001 | |||
| Etiology of cirrhosis | 0.851 | 0.725-0.999 | 0.048 | |||
| Portal vein hypertension | 1.826 | 1.288-2.589 | 0.001 | |||
| Liver function enzyme | 1.082 | 0.740-1.583 | 0.684 | |||
| (AST/ALT) | ||||||
| Child-Pugh classification | 2.930 | 2.169-3.958 | < 0.001 | 2.416 | 1.713-3.409 | < 0.001 |
| Serum AFP | 1.425 | 1.010-2.011 | 0.044 | |||
| CEUS pre-RFA | 0.421 | 0.297-0.598 | < 0.001 | |||
| Number of tumors | 1.765 | 1.212-2.570 | 0.003 | 1.588 | 1.031-2.447 | 0.036 |
| Tumor size | 1.587 | 1.104-2.283 | 0.013 | |||
| Risky location | 1.442 | 1.013-2.054 | 0.042 | |||
| Type of RFA electrodes | 0.449 | 0.264-0.764 | 0.003 | |||
| Primary technical success | 1.772 | 0.877-3.583 | 0.111 | |||
| Number of RFA sessions | 1.574 | 1.201-2.061 | 0.001 | 1.550 | 1.183-2.033 | 0.002 |
Table 7 Incidence of major complications in 548 treatment sessions
| Type of procedure-related complications1 | No. of events | Managements |
| Major complications | 10 (1.8) | |
| Bowel perforation | 1 | Surgically repaired |
| Seeding metastasis | 3 | Surgical resection |
| Pneumothorax or hemothorax | 3 | Drainage |
| Intraperitoneal hemorrhage | 1 | Ablation in site |
| Liver abscess | 1 | PTCD2 |
| Biliary stenosis | 1 | PTCD |
| No. of deaths | 1 (0.2) | (Bowel perforation) Surgically repaired |
- Citation: Yang W, Yan K, Goldberg SN, Ahmed M, Lee JC, Wu W, Zhang ZY, Wang S, Chen MH. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol 2016; 22(10): 2993-3005
- URL: https://www.wjgnet.com/1007-9327/full/v22/i10/2993.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i10.2993
